1-20 of 90
Kenneth C Anderson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improving Collection and Analysis of Overall Survival Data

Lisa R. Rodriguez, Nicole J. Gormley, Ruixiao Lu, Anup K. Amatya, George D. Demetri, Keith T. Flaherty, Ruben A. Mesa, Richard Pazdur, Mikkael A. Sekeres, Minghua Shan, Steven Snapinn, Marc R. Theoret, Rukiya Umoja, Jonathon Vallejo, Nicholas J.H. Warren, Qing Xu, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 3974–3982.
https://doi.org/10.1158/1078-0432.CCR-24-0919
Published: 13 September 2024
View article titled, Improving Collection and Analysis of Overall Survival Data
Open the PDF for Improving Collection and Analysis of Overall Survival Data in another window
Journal Articles

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

Keiji Kurata, Mehmet K. Samur, Priscilla Liow, Kenneth Wen, Leona Yamamoto, Jiye Liu, Eugenio Morelli, Annamaria Gulla, Yu-Tzu Tai, Jun Qi, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3956.
https://doi.org/10.1158/1078-0432.CCR-24-2112
Published: 03 September 2024
View article titled, Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Open the PDF for Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma in another window
Journal Articles

Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells

Annamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, Eugenio Morelli, Nicola Amodio, Cirino Botta, Maria Rita Pitari, Santo Giovanni Lio, Domenico Britti, Maria Angelica Stamato, Teru Hideshima, Nikhil C. Munshi, Kenneth C. Anderson, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2288.
https://doi.org/10.1158/1078-0432.CCR-24-1089
Published: 15 May 2024
View article titled, Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
Open the PDF for Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells in another window
Journal Articles

Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment

Alissa Huston, Xavier Leleu, Xiaoying Jia, Anne-Sophie Moreau, Hai T. Ngo, Judith Runnels, Judy Anderson, Yazan Alsayed, Aldo Roccaro, Sonia Vallet, Evdoxia Hatjiharissi, Yu-Tsu Tai, Peter Sportelli, Nikhil Munshi, Paul Richardson, Teru Hideshima, David G. Roodman, Kenneth C. Anderson, Irene M. Ghobrial
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 922.
https://doi.org/10.1158/1078-0432.CCR-24-0181
Published: 16 February 2024
View article titled, Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment
Open the PDF for Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment in another window
Journal Articles

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

Keiji Kurata, Mehmet K. Samur, Priscilla Liow, Kenneth Wen, Leona Yamamoto, Jiye Liu, Eugenio Morelli, Annamaria Gulla, Yu-Tzu Tai, Jun Qi, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1807–1821.
https://doi.org/10.1158/1078-0432.CCR-22-3668
Published: 01 May 2023
View article titled, BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Open the PDF for BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4593–4599.
https://doi.org/10.1158/1078-0432.CCR-22-3167
Published: 01 November 2022
View article titled, The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Open the PDF for The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission in another window
Journal Articles

Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response

Shih-Feng Cho, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1479–1481.
https://doi.org/10.1158/1078-0432.CCR-22-0015
Published: 14 April 2022
View article titled, Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response
Open the PDF for Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response in another window
Journal Articles

Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma

Johannes M. Waldschmidt, Jake A. Kloeber, Praveen Anand, Julia Frede, Antonis Kokkalis, Valeriya Dimitrova, Sayalee Potdar, Monica S. Nair, Tushara Vijaykumar, Nam Gyu Im, Amy Guillaumet-Adkins, Nitish Chopra, Hannah Stuart, Lillian Budano, Noori Sotudeh, Guangwu Guo, Clemens Grassberger, Andrew J. Yee, Jacob P. Laubach, Paul G. Richardson, Kenneth C. Anderson, Noopur S. Raje, Birgit Knoechel, Jens G. Lohr
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6432–6444.
https://doi.org/10.1158/1078-0432.CCR-21-2040
Published: 01 December 2021
View article titled, Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <em>BRAF</em>-Mutated Multiple Myeloma
Open the PDF for Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <em>BRAF</em>-Mutated Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression

Lijie Xing, Su Wang, Jiye Liu, Tengteng Yu, Hailin Chen, Kenneth Wen, Yuyin Li, Liang Lin, Phillip A. Hsieh, Shih-Feng Cho, Gang An, Lugui Qiu, Krista Kinneer, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5376–5388.
https://doi.org/10.1158/1078-0432.CCR-21-1621
Published: 01 October 2021
View article titled, BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
Open the PDF for BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression in another window
Includes: Supplementary data
Journal Articles

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Kenneth C. Anderson, Daniel Auclair, Stacey J. Adam, Amit Agarwal, Melissa Anderson, Hervé Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E. Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M. Ghobrial, Nicole J. Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J. Kelloff, Ilan R. Kirsch, Brandon Kremer, Ola Landgren, Elizabeth Lightbody, Oliver C. Lomas, Sagar Lonial, María-Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C. Munshi, Elizabeth K. O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J. Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A. Ross, Caroline C. Sigman, Katie L. Thoren, Suzanne Trudel, Gary Ulaner, Nancy Valente, Brendan M. Weiss, Elena Zamagni, Shaji K. Kumar
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5195–5212.
https://doi.org/10.1158/1078-0432.CCR-21-1059
Published: 01 October 2021
View article titled, Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Open the PDF for Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration in another window
Journal Articles

Facts and Hopes in Multiple Myeloma Immunotherapy

Adam S. Sperling, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4468–4477.
https://doi.org/10.1158/1078-0432.CCR-20-3600
Published: 15 August 2021
View article titled, Facts and Hopes in Multiple Myeloma Immunotherapy
Open the PDF for Facts and Hopes in Multiple Myeloma Immunotherapy in another window
Journal Articles

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

Irene M. Ghobrial, Chia-Jen Liu, Robert A. Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis-Pistofidis, Paul G. Richardson, Kenneth C. Anderson, Jacob Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Michael D. Robbins, Pamela S. Becker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 344–353.
https://doi.org/10.1158/1078-0432.CCR-19-0647
Published: 15 January 2020
View article titled, A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Open the PDF for A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia

Aldo M. Roccaro, Xavier Leleu, Antonio Sacco, Anne-Sophie Moreau, Evdoxia Hatjiharissi, Xiaoying Jia, Lian Xu, Bryan Ciccarelli, Christopher J. Patterson, Hai T. Ngo, Domenico Russo, Angelo Vacca, Franco Dammacco, Kenneth C. Anderson, Irene M. Ghobrial, Steven P. Treon
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4860.
https://doi.org/10.1158/1078-0432.CCR-19-2051
Published: 01 August 2019
View article titled, Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia
Open the PDF for Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia in another window
Journal Articles

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Güllü Gorgun, Diana Cirstea, Yiguo Hu, Jiro Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu-Tzu Tai, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (9): 2938.
https://doi.org/10.1158/1078-0432.CCR-19-0959
Published: 01 May 2019
View article titled, Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Open the PDF for Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma in another window
Journal Articles

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, Chia-Jen Liu, Noopur S. Raje, Andrew J. Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Jacquelyn Hedlund, Michael Martin, Craig Reynolds, Kenneth H. Shain, Ira Zackon, Laura Stampleman, Patrick Henrick, Bradley Rivotto, Kalvis T.V. Hornburg, Henry J. Dumke, Stacey Chuma, Alexandra Savell, Damian R. Handisides, Stew Kroll, Kenneth C. Anderson, Paul G. Richardson, Irene M. Ghobrial
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 478–486.
https://doi.org/10.1158/1078-0432.CCR-18-1325
Published: 15 January 2019
View article titled, A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma in another window
Journal Articles

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

Na Li, Michael A. Lopez, Maria Linares, Subodh Kumar, Stefania Oliva, Joaquin Martinez-Lopez, Lian Xu, Yan Xu, Tommaso Perini, William Senapedis, Erkan Baloglu, Masood A. Shammas, Zachary Hunter, Kenneth C. Anderson, Steven P. Treon, Nikhil C. Munshi, Mariateresa Fulciniti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 369–377.
https://doi.org/10.1158/1078-0432.CCR-18-1776
Published: 03 January 2019
View article titled, Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia
Open the PDF for Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia in another window
Includes: Supplementary data
Journal Articles

SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads

Krista Kinneer, John Meekin, Arnaud C. Tiberghien, Yu-Tzu Tai, Sandrina Phipps, Christine Mione Kiefer, Marlon C. Rebelatto, Nazzareno Dimasi, Alyssa Moriarty, Kyriakos P. Papadopoulos, Sriram Sridhar, Stephen J. Gregson, Michael J. Wick, Luke Masterson, Kenneth C. Anderson, Ronald Herbst, Philip W. Howard, David A. Tice
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6570–6582.
https://doi.org/10.1158/1078-0432.CCR-18-1300
Published: 13 December 2018
View article titled, SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Open the PDF for SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads in another window
Includes: Supplementary data
Journal Articles

Abstract PR13: p53-related protein kinase is a novel prognostic marker and therapeutic target in multiple myeloma

Francesca Cottini, Teru Hideshima, Yoshihisa Nozawa, Hiroto Ohguchi, Teruhiro Utsugi, Kenneth C Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): PR13.
https://doi.org/10.1158/1557-3265.HEMMAL17-PR13
Published: 14 December 2017
View article titled, Abstract PR13: p53-related protein kinase is a novel prognostic marker and therapeutic target in multiple myeloma
Journal Articles

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma

Morihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, Mehmet K. Samur, Yu-Tzu Tai, Nikhil C. Munshi, Masahiro Kizaki, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5225–5237.
https://doi.org/10.1158/1078-0432.CCR-17-0263
Published: 31 August 2017
View article titled, Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Open the PDF for Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet-Loiseau, Ann T. Farrell, Nicole J. Gormley, Shaji K. Kumar, Ola Landgren, Nikhil C. Munshi, Michele Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven I. Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. Little, Robert D. Loberg, Jens G. Lohr, Lata Mukundan, James L. Omel, Trevor J. Pugh, Gregory H. Reaman, Michael D. Robbins, A. Kate Sasser, Nancy Valente, Elena Zamagni
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 3980–3993.
https://doi.org/10.1158/1078-0432.CCR-16-2895
Published: 01 August 2017
View article titled, The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Open the PDF for The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications in another window
Includes: Supplementary data